Appendix table 2. Data summary of published reports on non-tuberculous mycobacterial endophthalmitis.

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Reference (n) | Patient characteristics (sex/age/underlying conditions) | Type(n) | Pathogenic organisms (n) | Cause (n) | Drug sensitivity (n) | Intraocular medications | Systemic medications | PPV | Eyeball removal | Initial BCVA worse than 6/60 | Final BCVA worse than 6/60 |
| Wasserman,1973 (1) | F/63leukemia | Endogenous | *M. avium* | Sepsis | - | - | R, cycloserine | no | yes | no | yes |
| Roussel,1989 (2)a | F/85, M/77 | Exogenous (2) | NTM gr IV (1),*M. chelonae* (1) | Cataract surgery | A | 2/2 IVT (A) | 2/2 (Ce2, TS)8 weeks | yes | no | 1/2 | 1/2 |
| Ambler,1989 (1) | M/67SOT, IMT | Endogenous | *M. chelonae* | Osteomyelitis of calcanei | A, M, Ca | IVT (A, V) | A, M, Ca | yes | no | yes | - |
| Cohen,1990 (1) | M/27AIDS | Endogenous | *M. avium* | Disseminated infection | - | - | A, Ce1 | - | no | - | - |
| Abu El-Asrar, 1995 (1) | M/65DM | Exogenous | *M. chelonae/**abscessus* | Cataract surgery | A, M, R, Ce2 | IVT (A, V) | A, V2 weeks | yes | no | yes | yes |
| Mutyala,1996 (1) | F/89 | Exogenous | *M. fortuitum* | Cataract surgery | A, F, Ca | IVT (A, V) | A, T4 weeks | yes | no | no | yes |
| Grenzbach,1996 (1) | M/60 | unclassified | NTM | - | - | - | A, Ce3, Cl, P | yes | yes | - | yes |
| Valenton,1996 (1)b | M/76 | Exogenous | *M. fortuitum* | Cataract surgery | - | IVT (A) | - | yes | no | - | 20/70 |
| Rosenbaum,1998 (1) | F/46AIDS | Endogenous | *M. avium* | Disseminated infection | - | IVT (A) | A, F, HRZE 12 weeks | no | yes | yes | yes |
| Uy,1999 (1) | M/19SJS, IMT | Exogenous | *M. abscessus* | Penetrating keratoplasty | A, M | IVT (A) | M16 weeks | yes | no | yes | yes |
| Ramaswamy, 2000 (1) | F/66 | Exogenous | *M. chelonae/**abscessus* | Cataract surgery | - | IVT (A, V) | A, HRZ6 weeks | yes | yes | no | yes |
| Gedde,2001 (1) | F/70 | Exogenous | *M. chelonae* | Penetrating keratoplasty | - | IVT (Ce1, Ce3) | M | no | no | yes | yes |
| Gobels,2002 (1) | M/32AIDS, TBLN (treated) | Endogenous | *M. kansasii* | - | H, R, E | no | H, R, E | no | yes | - | yes |
| Stephenson,2002 (1) | F | Exogenous | *M. terrae* | LASIK | - | - | - | yes | no | yes | yes |
| Scott,2003 (5) | 1 F, 4 Mage 62-77 | Exogenous (5) | *M. chelonae* | Cataract surgery (3), Corneal ulcer (1), IVT (1) | M (5),A (2) | 3/5 IVT (A, M, Ca) | 2/5 (R, M)4-28 weeks | 4/5 | 1/5 | 3/5 | 5/5 |
| Wilhelmus,2003 (1) | F/80 | Exogenous | *M. chelonae* | Cataract surgery | A, M | IVT (A) | M8 weeks | yes | no | - | yes |
| Marin-Casanova, 2003 (1) | F/65 | Exogenous | *M. abscessus* | Cataract surgery | A, M | IVT (A, Ce3) | M4 weeks | yes | no | no | no |
| Sungkanuparph, 2003 (2) | F/24, F/66 | Exogenous (2) | *M. chelonae/**abscessus* | Eye injury | - | - | 1/2 (T) | - | 1/2 | - | 1/2 |
| Benz,2003 (1) | M/62DM | Exogenous | *M. chelonae* | IVT | A, M | IVT (A, V) | M12 weeks | yes | yes | no | yes |
| Lalitha,2004 (6) | 5 F, 1 Mage 17-71 | Endogenous (3)Exogenous (3) | NTM (5),*M. chelonae/**abscessus* (1) | Disseminated infection (3), Cataract surgery (3) | - | - | - | no | 2/6 | - | 6/6 |
| Benz,2004 (3) c | M/33, M/62DM (1) | Endogenous (1)Exogenous (1) | *M. chelonae* (1),*M. triplex* (1) | IVT (1) | - | 1/3 IVT (A, V) | 1/3 M12 weeks | 1/3 | 1/3 | - | 1/3 |
| Spencer,2005 (1) | M/67 | Exogenous | *M. goodii* | Cataract surgery | A | IVT (A) | no | yes | no | yes | no |
| Stewart,2006 (1) | M/58AI, IMT | Exogenous | *M. chelonae/abscessus group* | Cataract surgery | A, M, Linezolid | IVT (A) | Ca, M24 weeks | yes | no | no | no |
| Matieli,2006 (1) | F/76 | Exogenous | *M. abscessus* | Cataract surgery | A, M, | IVT (A) | M16 weeks | yes | no | yes | yes |
| Modi,2007 (1) | M/66SOT, IMT | Endogenous | *M. haemophilum* | Skin abscess | R, T, F, M | IVT (A) | R, T, F, M40 weeks | yes | yes | no | yes |
| Palani,2007 (3) | 1 F, 2 Mage 58-72 | Exogenous (3) | *M. abscessus* (2),*M. fortuitum* (1) | Cataract surgery | A (3), F (2) | 1/3 IVT (A) | - | - | 1/3 | - | 2 |
| Jain,2008 (1) | F/55 | Exogenous | *M. chelonae* | Cataract surgery | - | IVT (A, V) | M1 week | yes | no | no | no |
| Durand,2008 (1) | M/77SJS | Exogenous | *M. abscessus* | Type 2 Boston keratoprosthesis | - | IVT | - | yes | no | - | LP |
| Chang,2010 (1) | F/88 | Exogenous | *M. abscessus* | DSEK | A, Ce2, F | IVT (Ce3, V) | no | yes | no | no | no |
| Sinawat,2011 (1) | F/47Sweet’s syndrome | Endogenous | NTM gr IV | Disseminated lymphadenitis | TS, Ca | no | Ca, M, F9 weeks | no | no | yes | no |
| Shirodkar,2011 (2)d | F/53, F/69Immunosuppressed (1) | Exogenous (2) | *M. chelonae/abscessus group* (2) | Cataract surgery | - | 2/2 IVT (A, Ce3, V) | 2/2 (M , R)1-4 weeks | 1/2 | 1/2 | 1/2 | 1/2 |
| Henry,2012 (1) | M/26 | Exogenous | *M. chelonae* | LASIK | A | - | - | - | - | HM | no |
| Couto,2013 (1) | F/34 | Exogenous | *M. gordonae* | Phakic IOL implant | H, R, M, A, F, TS | IC (F) | E, F, R16 weeks | no | no | no | no |
| Deobhakta,2012 (1)e | - | Exogenous | *M. fortuitum* | GDI | - | IVT Ce3, V | - | - | - | - | 20/50 |
| Rao,2013 (1) | M/13 | Exogenous | *M. fortuitum* | GDI | A, Ce1, F | IVT (A, Ce1) | no | - | no | - | yes |
| Rolfe,2013 (1) | F/56DM | Exogenous | *M. abscessus* | Traumatic eye with prosthesis | A, M | no | A, C, M24 weeks | no | yes | yes | yes |
| Mohan,2014 (1) | M/51 | Exogenous | *M. chelonae* | Scleral buckle removal | A | IVT (A) | - | - | no | no | no |
| Venkateswaran, 2014 (1) | M/68leukemia | Exogenous | *M. chelonae* | Corneal ulcer | A | IVT (A, Ce3, V, M) | no | yes | no | - | no |
| Medina Mendez,2015 (2)f | - | Exogenous (2) | *M. chelonae* (1),*M. fortuitum* (1) | GDI | - | 2/2 IVT (Ce3, V) | - | - | - | 20/50 1 | 0/2 |
| Paulose,2016 (5) | 3 F, 2 Mage 32-69 | Exogenous (5) | *M. chelonae* (3),*M. manitobense* (1),*M. fortuitum* (1) | Cataract surgery (3), PPV (1), DSEK (1) | A (5),F (4), V (2) | 5/5 IVT (A, Ce3, V) | - | 4/5 | 1/5 | 5/5 | 4/5 |
| Shah,2016 (19) | 9 F, 10 Mage 23-86DM (3), cancer (4), IMT (3), SOT (1), AIDS (1) | Endogenous (2)Exogenous (17) | *M. chelonae* (7),*M. chelonae/abscessus*  (7), *M. fortuitum* (3), *M. triplex* (1), *M. avium* (1) | Cataract surgery (7), GDI (6), IVT (2), PPV (1), Scleral buckle removal (1) Dissiminated infection (2) | A (14), F (3), M (12), Ce2 (2), Linezolid (4) | 14/19 IVT (A, Ce3, V) | 12/19 (M, A, R, F)1-4 weeks | 8/19 | 4/19 | 13/19 | 14/19 |
| Hung,2016 (2) | F/13, M/67 | Exogenous (2) | *M. abscessus* (2) | Cataract surgery (2) | - | 2/2 IVT A, Ce3, V) | 2/2 (V, Ce3, M, F) | 2/2 | 0/2 | 2/2 | 2/ 2 |
| Barkmeier,2016 (2) | F/74, M/72 | Exogenous (2) | *M. chelonae* (2) | Corneal ulcer (1), GDI (1) | - | 2/2 IVT (A) | 2/2 (M, Tigecycline) 24-48 weeks | 2/2 | 0/2 | 1/2 | 0/2 |
| Dave,2016 (1) | M/50liver cirrhosis | Exogenous | *M. manitobense* | Cataract surgery | A, Ce1, Ce2, F, V | IVT (A, Ce3, V) | F | yes | no | yes | no |
| Sharma,2017 (1) | M/38IMT, TB lung (treating) | Endogenous | *M. fortuitum+ M. bovis* | Disseminated infection | - | no | F, H, R, Z, E48 weeks | yes | no | yes | yes |
| Hsu,2018 (9) | 7F, 2Mage 59-82DM (1) | Exogenous (9) | *M. chelonae/abscessus group* (9) | Cataract surgery (9) | A | 9/9 IVT (A, V) | 9/9 (A, T, M)12-24 weeks | 9/9 | 2/9 | 5/9 | 9/9 |
| Hung,2018 (12) | 7F, 5Mage 13-86 | Exogenous (12) | *M. abscessus* (12) | Cataract surgery | A (8), Ca (2), Ce2 (1) | 12/12 IVT (A, Ce3, V) | 11/12 (A, Ce2, Ce3, F, M, R, T, V) 1-12 weeks | 7/12 | 5/12 | 10/12 | 12/12 |
| Di,2019 (15) | 8F, 7Mage 46-84DM (7) | Exogenous (15) | *M. fortuitum* (15) | Cataract surgery | - | IVT (Ce3, V) | F 1 week | 15/15 | 1/15 | 15/15 | 15/15 |
| Suganeswari,2020 (1) | F/28 | Exogenous | *M. abscessus* | PPV | Pi | IVT (Ce3, V, Pi) | - | no | no | yes | yes |
| Sharma,2020 (1) | M/30HIV | Endogenous | *M. avium* | - | - | IVT (Ce3, V) | - | yes | no | yes | no |

BCVA best-corrected visual acuity; F Female; M Male; SOT solid organ transplanted; IMT immunosuppressive therapy; AIDS acquired immunodeficiency syndrome; DM diabetes mellitus; SJS Steven-Johnson syndrome; TBLN tuberculous lymphadenopathy; AI autoimmune disease; TB tuberculosis; NTM non-tuberculous mycobacteria; NHL non-Hodgkin lymphoma

LASIK laser-assisted in situ keratomileusis; IVT intravitreous injection; IC intracameral injection; PPV pars plana vitrectomy; DSEK Descemet Stripping Endothelial Keratoplasty; IOL intraocular lens; GDI glaucoma drainage implantation;

A=Aminoglycosides; Ca=Carbapenems; Ce1=1st gen Cephalosporins; Ce2 D=2nd gen Cephalosporins; Ce3=3rd gen Cephalosporins; Cl=Clindamycin; E=Ethambuthol; F=Fluoroquinolones; H=Isoniazid; M=Macrolides; P=Penicillin; Pi=Piperacillin-tazobactam; R=Rifampicin, Rifampin; T=Tetracyclines; TS = Trimetroprim/Sulfamethoxazole; V=Vancomycin; Z=Pyrazinamide

a Data gathered from Scott, 2003, and Moorthy, 2012

b Data gathered from Moorthy, 2012

c Data gathered from Benz, 2003 and Shah, 2016

d Data gathered from Shah, 2016

e Data gathered from Medina Mendez, 2015

f Data gathered from Deobhakta, 2012